Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Getachew Mebrahtu Welay 1 Article
Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia
Getachew Mebrahtu Welay, Kefyalew Addis Alene, Berihun Assefa Dachew
Epidemiol Health. 2017;39:e2017001.   Published online December 28, 2016
DOI: https://doi.org/10.4178/epih.e2017001
  • 19,137 View
  • 395 Download
  • 19 Web of Science
  • 20 Crossref
AbstractAbstract PDF
Abstract
OBJECTIVES
Poor treatment outcomes of visceral leishmaniasis (VL) are responsible for the high mortality rate of this condition in resource-limited settings such as Ethiopia. This study aimed to identify the proportion of poor VL treatment outcomes in northwest Ethiopia and to evaluate the determinants associated with poor outcomes.
METHODS
A hospital-based retrospective study was conducted among 595 VL patients who were admitted to Kahsay Abera Hospital in northwest Ethiopia from October 2010 to April 2013. Data were entered into Epi Info version 7.0 and exported to SPSS version 20 for analysis. Bivariate and multivariate logistic regression models were fitted to identify the determinants of VL treatment outcomes. Adjusted odds ratio (aORs) with 95% confidence intervals (CIs) were used, and p-values <0.05 were considered to indicate statistical significance.
RESULTS
The proportion of poor treatment outcomes was 23.7%. Late diagnosis (≥29 days) (aOR, 4.34; 95% CI, 2.22 to 8.46), severe illness at admission (inability to walk) (aOR, 1.63; 95% CI, 1.06 to 2.40) and coinfection with VL and human immunodeficiency virus (HIV) (aOR, 2.72; 95% CI, 1.40 to 5.20) were found to be determinants of poor VL treatment outcomes.
CONCLUSIONS
Poor treatment outcomes, such as death, treatment failure, and non-adherence, were found to be common. Special attention must be paid to severely ill and VL/HIV-coinfected patients. To improve VL treatment outcomes, the early diagnosis and treatment of VL patients is recommended.
Summary

Citations

Citations to this article as recorded by  
  • Survival analysis of adult visceral leishmaniasis patients admitted to Metema Hospital, Metema, Ethiopia: a hospital-based cross-sectional study
    Habitamu Wudu, Chekol Alemu
    Transactions of The Royal Society of Tropical Medicine and Hygiene.2024; 118(11): 736.     CrossRef
  • Barriers and facilitators of visceral leishmaniasis case management in the Amhara Region, Northwest Ethiopia: an exploratory qualitative study
    Yared Mulu Gelaw, Jean-Pierre Gangneux, Getu Degu Alene, Florence Robert-Gangneux, Adisu Abebe Dawed, Mohammed Hussien, Wendemagegn Enbiale
    BMC Public Health.2024;[Epub]     CrossRef
  • Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia
    Muluneh Ademe, Yaneth Osorio, Rawliegh Howe, Saba Atnafu, Tadele Mulaw, Helina Fikre, Bruno L. Travi, Asrat Hailu, Peter C. Melby, Tamrat Abebe
    Tropical Medicine and Infectious Disease.2023; 8(1): 36.     CrossRef
  • Fever of Unknown Origin and Splenomegaly: A Case Report of Visceral Leishmaniasis Diagnosed By Metagenomic Next-Generation Sequencing
    Lan-Qing Li, Yiju He, Ting Liu, Jing Zhou, En-Qiang Chen
    Future Microbiology.2023; 18(11): 699.     CrossRef
  • Trend of Visceral Leishmaniasis at Medicine Sans Frontier’s Abdurafi Treatment Center, West Armachiho District, Ethiopia, 2009-2015, a retrospective descriptive analysis
    Sisay Awoke, Sefonias Getachew, Yimer Seid, Tatek Bogale
    Journal of Interventional Epidemiology and Public Health.2022;[Epub]     CrossRef
  • Zoonotic Diseases in the eastern region of the Iraqi capital, between 2010-2016
    A S Barrak, O A Saeed, MTA Mohammed
    IOP Conference Series: Earth and Environmental Science.2021; 779(1): 012008.     CrossRef
  • Inequalities of visceral leishmaniasis case-fatality in Brazil: A multilevel modeling considering space, time, individual and contextual factors
    Gláucia Cota, Astrid Christine Erber, Eva Schernhammer, Taynãna Cesar Simões, Alberto Novaes Ramos
    PLOS Neglected Tropical Diseases.2021; 15(7): e0009567.     CrossRef
  • Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia
    Aschalew Tamiru, Rezika Mohammed, Saba Atnafu, Girmay Medhin, Asrat Hailu, Peter C. Melby
    PLOS Neglected Tropical Diseases.2021; 15(8): e0009713.     CrossRef
  • Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects
    O.F. Davies-Bolorunduro, O. Osuolale, S. Saibu, I.A. Adeleye, N.S. Aminah
    Heliyon.2021; 7(8): e07710.     CrossRef
  • Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis
    Mehdi Mohebali, Yonas Yimam
    BMC Infectious Diseases.2020;[Epub]     CrossRef
  • Incidence of Mortality and Its Predictors Among Adult Visceral Leishmaniasis Patients at the University of Gondar Hospital: A Retrospective Cohort Study


    Yigizie Yeshaw, Adino Tesfahun Tsegaye, Solomon Gedlu Nigatu
    Infection and Drug Resistance.2020; Volume 13: 881.     CrossRef
  • Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations
    Kyung-Hwa Baek, Laura Piel, Thibault Rosazza, Eric Prina, Gerald F. Späth, Joo Hwan No
    Pathogens.2020; 9(5): 393.     CrossRef
  • Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening
    S. Lamotte, N. Aulner, G. F. Späth, E. Prina
    Scientific Reports.2019;[Epub]     CrossRef
  • Visceral Leishmaniasis Treatment Outcome and Associated Factors in Northern Ethiopia
    Kidu Gidey, Desalegn Belay, Berhane Yohannes Hailu, Tesfaye Dessale Kassa, Yirga Legesse Niriayo
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
    Dinesh Mondal, Prakash Ghosh, Rajashree Chowdhury, Christine Halleux, Jose A. Ruiz-Postigo, Abdul Alim, Faria Hossain, Md Anik Ashfaq Khan, Rupen Nath, Malcolm S. Duthie, Axel Kroeger, Greg Matlashewski, Daniel Argaw, Piero Olliaro
    Frontiers in Microbiology.2019;[Epub]     CrossRef
  • Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia
    Helina Fikre Tamiru, Yohana James Mashalla, Rezika Mohammed, Gloria Thupayagale Tshweneagae
    BMC Infectious Diseases.2019;[Epub]     CrossRef
  • The criminal association of Leishmania parasites and viruses
    Matteo Rossi, Nicolas Fasel
    Current Opinion in Microbiology.2018; 46: 65.     CrossRef
  • Leishmaniasis in Ethiopia: A systematic review and meta-analysis of prevalence in animals and humans
    Ayalew Assefa
    Heliyon.2018; 4(8): e00723.     CrossRef
  • Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis
    Eyob Alemayehu Gebreyohannes, Akshaya Srikanth Bhagvathula, Tadesse Melaku Abegaz, Mohammed Assen Seid
    Infectious Diseases of Poverty.2018;[Epub]     CrossRef
  • A preliminary survey of major diseases of ruminants and management practices in Western Tigray province, northern Ethiopia
    Getachew Mebrahtu Welay, Dawit Gebremichael Tedla, Gebreyohans Gebru Teklu, Shishay Kahsay Weldearegay, Mearg Belay Shibeshi, Haftom Hadush Kidane, Berhe Beyene Gebrezgiabher, Teklehaymanot Huluf Abraha
    BMC Veterinary Research.2018;[Epub]     CrossRef

Epidemiol Health : Epidemiology and Health
TOP